C4A and systemic lupus erythematosus: In the present study, we sought to refine the use of sVCAM-1 as a biomarker in SLE, and to determine whether longitudinal sampling of sVCAM-1 could be of clinical utility in addition to conventional serum markers of disease activity such as anti-double-stranded DNA (anti-dsDNA) antibody levels and complement C3 and C4 levels.